The company’s R&D expenditure reached RMB4.61 billion, maintaining a high investment rate of 29.8% of total revenue. This capital fueled seven domestic regulatory approvals, including three novel medicines. Currently, the pipeline includes 17 programs in Phase III clinical trials, signaling a robust transition from research to potential market entry.
In section Releases
Hengrui Pharma Shifts Strategy as Non-Oncology Drugs Drive Growth
With innovative therapies accounting for over 63% of drug sales, Shanghai-based Hengrui Pharma reported RMB15.46 billion in revenue for the first half of 2026. The company is pivoting from its traditional oncology roots, as non-oncology innovative drug sales surged by nearly 74% compared to the previous year.
Metabolic health has emerged as a specific area of strength. Clinical data for the GLP-1 receptor agonist HRS-7535 showed a mean body-weight reduction of 11.1% in obesity studies, with a new drug application expected to follow. Beyond domestic efforts, Hengrui continues to leverage international partnerships, having finalized 13 overseas transactions since 2023 with a combined potential value of US$42 billion. The strategy of spinning off assets into independent entities has also yielded results, with both Kailera Therapeutics and Braveheart Bio successfully completing Nasdaq listings this year.
Comments (0)
No comments yet. Be the first!